

80 Investors: Longevity in Switzerland



3wVentures



3wVentures provides seed money and venture capital to international internet startups. As 3wVentures' clients focus on early stage projects and prototypes, the company's investments and co-investments target a volume of up to USD 250,000. 3wVentures is located in Switzerland and backed by Yves Latour and Arvin Zuberbuehler. 3wVentures has invested early stage venture capital in these startup companies: forAtable.com, Lunchgate, UEPA! etc.

Web site:	3wventures.com
Number of Investments:	44
Total Investments:	\$23.3M
Founded in:	2007
Based in:	Herisau, Switzerland
Sector:	P3, AgeTech
Investment in Switzerland companies:	Pregnolia, Abionic
Stages:	Early Stage Venture, Seed

Aescap Venture



Aescap 2.0 is an open-end fund that invests in publicly listed biotech / life sciences companies. It invests in highly innovative companies that develop and market new medicines and to a lesser extent diagnostics and/or medical devices. Entry into and exit from the fund is possible twice per month. The life sciences market is a large and fast-growing market where breakthrough innovations can be harnessed in a global and profitable manner.

Aescap 2.0 has a focused portfolio, investing in approximately 18 companies. Within this focus it will ensure that the portfolio is diversified over different diseases and company development phases. The Fund's objective is to make an annual net return (after deduction of costs) of 20% over the mid-term (4-5 years).

Web site:	aescap.com
Number of Investments:	26
Total Investments:	\$30.5M
Founded in:	2005
Based in:	Amsterdam, The Netherlands
Sector:	Regenerative Medicine
Investment in Switzerland companies:	Vivendy Therapeutics
Stages:	Early Stage Venture, Late Stage Venture

Angel Investment Network



Angel Investment Network is a London-based investment company founded in 2004 whose aim is to connect entrepreneurs and investors. Today they have 35+ angel networks worldwide covering over 80 countries. They have over 150,000 investor members and over 600,000 entrepreneurs have signed up to use their services. Angel Investment Network brings together businesses looking for investment and investors with the capital, contacts and knowledge to help them succeed.

Web site:	angelinvestmentnetwork.co
Number of Investments:	29
Total Investments:	\$6.3M
Founded in:	2004
Based in:	London, UK
Sector:	P3
Investment in Switzerland companies:	healthbank innovation AG
Stages:	Convertible Note, Crowdfunding, Early Stage Venture, Late Stage Venture, Seed, Venture

Arthurian Life Sciences



Arthurian Life Sciences Ltd was established by Europe's leading biotech entrepreneur Professor Sir Chris Evans OBE to act as General Partner of the Wales Life Sciences Investment Fund, a £100 million fund and key part of the Welsh Government's Life Sciences initiative. The Fund will invest in Life Sciences and related medical, pharmaceutical and healthcare companies currently based in Wales, and also in companies from across the UK, Europe and the rest of the world, where such investment will bring meaningful developmental and economic benefit to Wales. The Fund will make initial investments of between £500,000 and £5,000,000, and will preserve capital to provide follow-on investments. Arthurian will spread investments by risk, sub-sector, age or funding requirement and will consider companies of all sizes, both start-ups and mature companies, and will do both early & late stage investments.

Web site:	arthurianlifesciences.co
Number of Investments:	8
Total Investments:	\$100M
Founded in:	2012
Based in:	London, UK
Sector:	P3
Investment in Switzerland companies:	CeQur
Stages:	Seed, Series B, Series C

BioMedPartners



BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. Their focus is on Switzerland and surrounding EU countries Germany, Austria, France, Italy and Benelux. BioMedPartners mostly invests in drug development and, to a lesser degree, in diagnostics and medical technology, biotechnology, diagnostics. The amount they aim to invest over the life time of their portfolio companies is up to CHF 10 million. BioMedPartners often plays the lead or co-lead investor role structuring the transaction and syndicating with other venture capital firms.

Web site:	biomedvc.com
Number of Investments:	65
Total Investments:	\$61M
Founded in:	2002
Based in:	Basel, Switzerland
Sector:	P3, Regenerative Medicine
Investment in Switzerland companies:	Genkyotex, Amal Therapeutics
Stages:	Early Stage Venture, Late Stage Venture

BlueOcean Ventures



BlueOcean Ventures invests in early stage medical device and life science companies. Unlike other funds the four General Partners of BlueOcean Ventures, Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz and Thomas Zehnder, have a long-standing track record in building, managing and coaching start-up companies. BlueOcean Ventures supports their portfolio companies with a large network of experts and industry contacts.

Web site:	blueocean-ventures.com
Number of Investments:	11
Total Investments:	\$3.8M
Founded in:	Undisclosed
Based in:	Geneva, Switzerland
Sector:	P3
Investment in Switzerland companies:	Abionic
Stages:	Early Stage Venture

Boehringer Ingelheim Venture Fund



For more than 130 years, Boehringer Ingelheim has been committed to the research, development, and manufacturing of new medications with high therapeutic value for people and animals. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development. They are proud of addressing some of the most challenging healthcare issues. Their vision – value through innovation – has always characterized the collaborative work, and is for them simultaneously a fundamental requirement and a driving force. Headquartered in Ingelheim, Germany, Boehringer Ingelheim employs more than 50,000 employees.

Web site:	boehringer-ingelheim-venture.com
Number of Investments:	35
Total Investments:	\$66M
Founded in:	1973
Based in:	Ingelheim Am Rhein, Germany
Sector:	P3
Investment in Switzerland companies:	Amal Therapeutics, NBE-Therapeutics
Stages:	Early Stage Venture, Seed

BVGroup



BV Holding AG is a private equity firm specializing in management buy-outs and buy-ins; succession financing; change in shareholder structure; growth, expansion, and acquisition; innovation; growth financing including early and late stage investments; and restructuring. Within growth financing the firm seeks to invest in media technology, life science, Information Technology, telecommunication technology, industry material and process technology.

Web site:	bvgroup.ch
Number of Investments:	3
Total Investments:	Undisclosed
Founded in:	1997
Based in:	Gümligen, Switzerland
Sector:	Regenerative Medicine
Investment in Switzerland companies:	Covalys Biosciences
Stages:	Series C

CADFEM



CADFEM provides engineering analysis software sales, consultancy, training and technical services to a variety of global and UK customers. These products provide engineers with broad, high end analysis functionality for the development of leading edge products and state of the art manufacturing processes. Cumulatively their group of 18 skilled and motivated staff have more than 100 years experience in providing and supporting simulation led engineering solutions. Their expertise is spread across a wide range of engineering sectors: medical devices, renewable energy, aerospace, automotive, civil engineering, mechanical engineering, power engineering amongst others. They have expertise in linear and nonlinear, static and dynamic, implicit and explicit, stress analyses, steady state and transient heat transfer analysis, computational fluid dynamics analysis, fluid-structure analysis.

Web site:	cadfem-us.com
Number of Investments:	1
Total Investments:	\$3.8M
Founded in:	1985
Based in:	Farmington Hills, MI, United States
Sector:	AgeTech
Investment in Switzerland companies:	Pregnolia
Stages:	Undisclosed

Capital Initiative



Since its creation in 1998, Capital Initiative has continued to work to financially support French SMEs and overcome their difficulties in accessing financing. Company tested all possible forms of intervention within the framework of the law and financial regulations. This experience has reinforced the Temporary Asset Purchase (TAP) as the optimal device for joining the interests of all stakeholders by combining their goal of safeguarding employment.

The TAP, model validated by the Prudential Control Authority of the Banque de France, consists of the repurchase of an asset (furniture or real estate) of the customer immediately followed by its hiring. At the end of the lease, for less than 5 years, the property is resold at the purchase price.

Web site:	capital-initiative.fr
Number of Investments:	4
Total Investments:	\$21M
Founded in:	1998
Based in:	Sausheim, France
Sector:	P3
Investment in Switzerland companies:	Xigen
Stages:	Early Stage Venture, Late Stage Venture

CDC Enterprises



CDC Entreprises was a portfolio management company approved by the AMF (Autorité des Marchés Financiers, the French Financial Markets Authority), and a wholly-owned subsidiary of the French Caisse des Dépôts. CDC Entreprises is in charge of the group's public interest activities in the field of private equity investments dedicated to SMEs. CDC Entreprises was a direct investor and a funds-of-funds investor in SMEs, on a national and regional level, covering all private equity segments from technology seed funding to small-cap buy-outs. The mission of CDC Entreprises is to encourage the emergence of companies experiencing sustainable growth by strengthening their equity. In 2013 Caisse des Dépôts et Consignations and EPIC BPI-Groupe united to create a joint venture - Bpifrance, a French investment bank.

Web site:	bpifrance.fr
Number of Investments:	21
Total Investments:	\$4M
Founded in:	1994
Based in:	Paris, France
Sector:	P3
Investment in Switzerland companies:	Kuros Biosciences
Stages:	Early Stage Venture, Late Stage Venture, Private Equity

Deutsche Venture Capital



Deutsche Venture Capital was acquired by VCG Venture Capital Gesellschaft mbH. It is a venture capital arm of Deutsche Bank AG specializing in seed, start-up, and expansion capital investments. The firm prefers to invest in life sciences and technology companies. Within the life sciences sector it focuses on biotechnology including therapeutic and diagnostic product development and platform technologies and medical devices. The firm prefers to invest in information technology, telecommunication, semiconductor, industrial technologies, information management, application management, infrastructure management, communication applications, communication platforms, network infrastructure, optics, automation, sensors, electronics, and materials within the technology sector.

Web site:	-
Number of Investments:	21
Total Investments:	\$13.6M
Founded in:	1998
Based in:	München, Germany
Sector:	P3
Investment in Switzerland companies:	Roche Glycart
Stages:	Undisclosed

dievini Hopp Biotech holding



Dievini is an active investor in Life and Health Sciences companies and is dedicated to the coaching and support of the management teams in corporate and business development. Dievini's focus is on innovative therapeutics and diagnostics, which are shown to lead to novel treatment regimens allowing doctors to treat patients with life-threatening diseases better and safer than they can today. Dievini, therefore, is largely invested in companies with unique and first-in-class diagnosis and therapy approaches. The indication focus is in oncology, neurology, infectious diseases, cell therapy and drug delivery systems. In molecular diagnostics, the primary focus is on systems and products in personalized medicine to support and allow individually improved therapy success with reduced adverse events.

Web site:	dievini.de
Number of Investments:	15
Total Investments:	\$20M
Founded in:	2005
Based in:	Walldorf, Germany
Sector:	P3
Investment in Switzerland companies:	AC Immune
Stages:	Late Stage Venture

EASME



The Executive Agency for Small and Medium-sized Enterprises (EASME) has been set up by the European Commission to manage on its behalf several EU programs.

EASME is in charge of managing SME, environment, energy and maritime projects funded under COSME, Horizon 2020, LIFE, and EMFF. EASME also organizes the European Sustainable Energy Week (EUSEW).

Web site:	ec.europa.eu/easme
Number of Investments:	2601
Total Investments:	Undisclosed
Founded in:	2014
Based in:	Brussels, Belgium
Sector:	P3
Investment in Switzerland companies:	CyanoGuard
Stages:	Grant

Eclosion Ventures



Eclosion Ventures manages the Eclosion life science investment fund, which focuses on translating cutting edge science into biotechnology companies developing transformational best-in-diseases therapeutics and platform technologies. Eclosion's approach is defined by its unique entrepreneurial mindset leading to a strong operational and investment commitment to start-up enterprises. Eclosion is driven by an experienced management team which brings together scientific, operational and financial expertise and a successful track record of company creation, value generation and development of new therapeutics that will transform human healthcare.

Web site:	eclosionventures.com
Number of Investments:	15
Total Investments:	Undisclosed
Founded in:	2001
Based in:	Geneva, Switzerland
Sector:	P3
Investment in Switzerland companies:	Geneva Biotech Center
Stages:	Early Stage Venture, Late Stage Venture, Seed

Edmond de Rothschild Private Equity



EDMOND
DE ROTHSCHILD

The Edmond de Rothschild Group is a leader in private equity, using its family experience to assist companies. Their teams are not merely financial investors. They are active partners in company growth and work closely with company executives on value creation. Their Group has long understood that taking environmental, social and governance (ESG) issues into consideration is key to both risk management and value creation for all of the companies in its portfolio. Each area of expertise applies considerations from outside the realm of finance to its specific investment strategy and implements the highest ESG standards.

Web site:	edmond-de-rothschild.com
Number of Investments:	6
Total Investments:	\$18M
Founded in:	1953
Based in:	Paris, France
Sector:	P3
Investment in Switzerland companies:	OncoEthix
Stages:	Private Equity

Endeavour Vision



Endeavour Vision is a growth investor in exceptional private medtech companies, and an ideal partner for medtech entrepreneurs. Headquartered in Geneva, Switzerland with a presence in the United States, the Endeavour Vision team comprises experienced investors, seasoned entrepreneurs and medtech specialists, all committed to helping entrepreneurs grow and develop thriving businesses. Endeavour's latest \$275 million fund is fully dedicated to investing in European and US medtech companies that seek worldwide growth and aim to improve the quality and cost of care for patients across the globe.

Web site:	endeavourvision.com
Number of Investments:	43
Total Investments:	\$22.2M
Founded in:	2000
Based in:	Geneva, Switzerland
Sector:	P3
Investment in Switzerland companies:	OncoEthix
Stages:	Early Stage Venture, Late Stage Venture, Venture

Erfindungs Verwertung



Erfindungs Verwertung AG is a venture capital firm specializing in seed and startup investments. The firm also does incubation, spin-off and investments in small and medium sized companies. It seeks to invest in life sciences industries such as pharmaceutical, biochemistry, biotechnology, biomedicine, diagnostic, R&E platforms, medical technology, drug development, molecular biology, physics and nanotechnology. ErfindungsVerwertung AG was founded in 1996 and is based in Basel, Switzerland. ErfindungsVerwertung AG is subsidiary of Basellandschaftliche Kantonalbank and Basler Kantonalbank.

Web site:	eva-basel.ch
Number of Investments:	1
Total Investments:	\$2.6M
Founded in:	1996
Based in:	Basel, Switzerland
Sector:	Regenerative Medicine
Investment in Switzerland companies:	Covalys Biosciences
Stages:	Early Stage Venture

ETP Ventures

ETP Ventures is a biomedical venture capital firm that invests as early as the seed stage and as late as post-IPO rounds. ETP is comfortable acting as a lead investor or partner in syndicated rounds where the key elements for success are already in place.

Web site:	-
Number of Investments:	1
Total Investments:	\$20M
Founded in:	Undisclosed
Based in:	San Francisco, CA, USA
Sector:	P3
Investment in Switzerland companies:	Cellestia Biotech
Stages:	Undisclosed

Eurostars



The Eurostars Programme is a joint programme between EUREKA and the European Commission and the first European funding and support programme to be specifically dedicated to research-performing SMEs. Eurostars stimulates them to lead international collaborative research and innovation projects by easing access to support and funding. The Eurostars Programme is a European Joint Programme dedicated to the R&D performing SMEs, and co-funded by the European Communities and 36 EUREKA member countries.

Web site:	eurostars-eureka.eu
Number of Investments:	22
Total Investments:	\$60.32M
Founded in:	1985
Based in:	Brussels, Belgium
Sector:	P3
Investment in Switzerland companies:	GenomSys
Stages:	Undisclosed

FONGIT



FONGIT, the “Fondation Genevoise pour l’Innovation Technologique”, is Switzerland’s premier innovation incubator supporting innovative tech ventures in Geneva. Founded in 1991, Fongit has an excellent track record of building successful companies. They are a private, non-profit foundation, whose mission is to transform technology into social & economic value in the Geneva region. FONGIT benefits from the support of the business incubator program of the State of Geneva. Fongit currently hosts 55+ innovative companies representing 350+ employees in 5000+ m2 of professionally-equipped offices & laboratory space. Their entrepreneurs develop innovative Fintech, IT, Engineering, and Medtech companies.

Web site:	fongit.ch
Number of Investments:	29
Total Investments:	Undisclosed
Founded in:	1991
Based in:	Geneva, Switzerland
Sector:	P3
Investment in Switzerland companies:	Aptissen
Stages:	Seed

Forbion Capital Partners



Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed \$500M, split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.

Web site:	forbion.com
Number of Investments:	79
Total Investments:	\$54.7M
Founded in:	2006
Based in:	Naarden, The Netherlands
Sector:	P3
Investment in Switzerland companies:	Prexton Therapeutics, Roche Glycart
Stages:	Early Stage Venture, Late Stage Venture

Genevest Consulting Group



Genevest Consulting Group is a venture capital firm specializing in seed, start-ups, early-mid-late stage, and expansion investments. Genevest Consulting Group seeks to invest in technology, information technology, communications, material sciences, medical technology, cleantech, and life sciences. It prefers to invest in Europe and Switzerland and also invests selectively in the United States and in Israel.

Web site:	-
Number of Investments:	5
Total Investments:	\$20.5M
Founded in:	1985
Based in:	Geneva, Switzerland
Sector:	P3
Investment in Switzerland companies:	Kuros Biosciences
Stages:	Early Stage Venture

Gilde Healthcare



Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million (\$900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Web site:	gildehealthcare.com
Number of Investments:	67
Total Investments:	\$41.93M
Founded in:	1982
Based in:	Utrecht, The Netherlands
Sector:	P3
Investment in Switzerland companies:	Roche Glycart
Stages:	Early Stage Venture, Late Stage Venture, Private Equity

Global Life Science Ventures



Global Life Science Ventures (GLSV) was a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US.

Web site:	global-life-science-ventures.com
Number of Investments:	30
Total Investments:	\$192.05M
Founded in:	1996
Based in:	München, Germany
Sector:	P3
Investment in Switzerland companies:	Roche Glycart
Stages:	Debt, Early Stage Venture, Late Stage Venture

GoBeyond



GoBeyond Investing is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders. Its clients are individuals, family offices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Web site:	gobeyondinvesting.com
Number of Investments:	167
Total Investments:	Undisclosed
Founded in:	2013
Based in:	Zurich, Switzerland
Sector:	P3
Investment in Switzerland companies:	Cellestia Biotech, BioVersys
Stages:	Early Stage Venture

HBM Partners



HBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies. HBM Partners has a team of experienced professionals to source, analyse and engage in investments in biopharma, medical devices and diagnostics industries. HBM Partners has a track-record of over 100 investments that resulted so far in significant value creation by more than 60 trade sales and IPOs since inception.

HBM Partners is regulated by FINMA and advises SIX listed HBM Healthcare Investments and further specialised public and private equity investment products.

Web site:	hbmpartners.com
Number of Investments:	24
Total Investments:	Undisclosed
Founded in:	2001
Based in:	Grand Cayman, Cayman Islands
Sector:	P3
Investment in Switzerland companies:	APR Applied Pharma Research
Stages:	Debt, Early Stage Venture, Late Stage Venture, Seed

HealthCare Royalty Partners



HealthCare Royalty Partners (“HCR”) is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage assets. HCR has raised over \$4.7 billion in cumulative capital commitments and has offices in Stamford (CT), Boston, London and San Francisco. The HCR team consists of 32 individuals (including their Senior Advisors), Their investment platform is designed to serve as a long-term capital resource for company’s partners; flexible and directly aligned with their business models and objectives. Team that utilizes multiple investment approaches to help partners achieve their goals including: customized debt, royalty monetization, and revenue participation financings. Since 2003, HCR's senior professionals have completed more than 60 healthcare investments.

Web site:	healthcareroyalty.com
Number of Investments:	14
Total Investments:	\$50M
Founded in:	2007
Based in:	Stamford, CT, USA
Sector:	P3
Investment in Switzerland companies:	Cardiorentis
Stages:	Debt, Private Equity

Helsinn Investment Fund



The Helsinn Investment Fund focuses on privately-owned companies with early stage technologies in Cancer Supportive Care, Cancer Diagnostics and Cancer Therapeutics, among other areas close to Helsinn's interests such as dermatology, metabolism and gastro-intestinal disease. These technologies range from biotech to pharma, medical devices and food supplements.

As well as these investments, Helsinn International Services, Sarl, has signed collaboration agreements with Centre Scientifique de Monaco and Lyfebulb U.S.

Web site:	helsinninvestmentfund.com
Number of Investments:	12
Total Investments:	\$44.4M
Founded in:	2016
Based in:	Monaco, Principality of Monaco
Sector:	P3
Investment in Switzerland companies:	Amal Therapeutics
Stages:	Early Stage Venture

Hercules Capital



The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing.

Web site:	htgc.com
Number of Investments:	104
Total Investments:	\$55M
Founded in:	2003
Based in:	Palo Alto, CA, USA
Sector:	Regenerative Medicine
Investment in Switzerland companies:	Axovant Sciences
Stages:	Debt, Early Stage Venture, Late Stage Venture, Post-Ipo, Seed

High-Tech Gründerfonds



High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF's focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences. To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds.

Web site:	high-tech-gruenderfonds.de
Number of Investments:	546
Total Investments:	\$48M
Founded in:	2005
Based in:	Bonn, Germany
Sector:	P3
Investment in Switzerland companies:	Amal Therapeutics
Stages:	Early Stage Venture, Seed

Hitachi Chemical Diagnostics



Hitachi Chemical Diagnostics, Inc. manufactures vitro allergy diagnostics. The company offers CLA Allergen-Specific IgE, a serum test assay; CLA-1 Luminometer, an in vitro allergy diagnostic system; AP 720S, a semi-automated in vitro allergy diagnostic system; and AP 1800, an automated in vitro allergy diagnostics system; and CLA-1, a data management software for physicians and laboratories to integrate database functionality into the testing process. It also offers ExoComplete 96-well plate kit and ExoComplete tube kit, an integrated system for exosome collection to mRNA purification used for the research use of molecular biology applications. The company markets its products through laboratories and distributors worldwide. Hitachi Chemical Diagnostics, Inc. was formerly known as MAST Immunosystems, Inc. and changed its name to Hitachi Chemical Diagnostics, Inc. in July 2000.

Web site:	hcdiagnostics.com
Number of Investments:	Undisclosed
Total Investments:	Undisclosed
Founded in:	1996
Based in:	Mountain View, CA, USA
Sector:	P3
Investment in Switzerland companies:	Biocartis
Stages:	Undisclosed

HS LifeSciences



HS LifeSciences was established in 2008 by seasoned biotech entrepreneurs with many years of experience in managing biotech companies. The lessons learned over the years have been distilled into a new business model centered on the foundation and growth of new life sciences companies without the need for conventional multiple rounds of equity-based financing. HS LifeSciences supports new life sciences companies during their foundation and early growth phases by complementing the scientific founders' R&D vision with management, financial and commercial experience. Patient benefit remains the utmost priority for their portfolio companies and company's overriding goal is to bring novel therapies to the market in the fastest possible manner. Their business model enables portfolio companies to pursue their role as innovation powerhouses bringing together their medical innovation with the biopharmaceutical industry.

Web site:	hslifesciences.com
Number of Investments:	2
Total Investments:	\$9M
Founded in:	2008
Based in:	Zurich, Switzerland
Sector:	P3
Investment in Switzerland companies:	CT Atlantic
Stages:	Early Stage Venture

Idinvest Partners



Idinvest Partners is a pan-European private equity manager focused on the low and middle market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primary investments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting. Idinvest Partners' recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Convertteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Web site:	idinvest.com
Number of Investments:	333
Total Investments:	\$10.1M
Founded in:	1997
Based in:	Paris, France
Sector:	P3
Investment in Switzerland companies:	Auris Medical
Stages:	Early Stage Venture, Late Stage Venture, Seed

Index Ventures



Index
Ventures

Index Ventures is a venture capital firm specializing in seed stage, very-early stage, expansion, early stage, mid stage, late stage, and growth stage start-ups, series A, and series B rounds. It makes investments in information technology with a focus on communications, security, applications and services media,, water purification, B2B commerce, SaaS, open source, networking, enabling platform, components and EDA, consumer and internet infrastructure, enterprise software, software, mobile software, bitcoin, gaming, and wireless, and cloud computing; life sciences and healthcare with a focus on healthcare infrastructure, antibodies, molecule drugs, drug discovery, drug development, screening and diagnostics and medical devices; education; commerce; marketplace; financial services, and payment; branded consumer products ; green technology; biotechnology.

Web site:	indexventures.com
Number of Investments:	731
Total Investments:	\$9M
Founded in:	2008
Based in:	San Francisco, CA, USA
Sector:	P3
Investment in Switzerland companies:	OncoEthix
Stages:	Early Stage Venture, Late Stage Venture, Seed

Innovation Capital



Innovation Capital is an international venture capital firm based in Paris with a local presence in the Silicon Valley. With over 450 M€ under management, their current focus is on venture and growth investments in the Innovation Healthcare Services space in Europe. Innovation Capital's aim is to create value by providing talented entrepreneurs with the resources, experience, and network necessary to turn innovative technologies into great businesses. This fund is the first sector fund supporting the Silver Economy. This term is used actually to define the Senior market, all products and services that are expected to improve disability-free life expectancy or to help dependent elderly people and their caregivers on a day-to-day basis.

Web site:	innovationcapital.fr
Number of Investments:	59
Total Investments:	\$12.4M
Founded in:	1996
Based in:	Paris, France
Sector:	P3
Investment in Switzerland companies:	Kuros Biosciences
Stages:	Early Stage Venture, Late Stage Venture, Seed

investiere

investiere

venture capital

investiere is a digital venture capital platform with offices in Switzerland. Company source deals mainly from Switzerland's leading universities and increasingly from other European countries too. Since its launch in 2010, investiere has participated in over 70 funding rounds, co-investing with reputable VC funds, business angels and corporates. They make investment opportunities available on their online platform for qualified investors around the world (except US). The minimum ticket size is CHF 10'000, allowing private investors to choose what they want to invest in, to diversify easily and rely on in-house expertise to choose the most promising startups. Several institutional investors such as a large Swiss pension fund and numerous corporates rely on the deal sourcing, screening and evaluation for their own venture capital investments.

Web site:	investiere.ch
Number of Investments:	79
Total Investments:	\$3.3M
Founded in:	2007
Based in:	Zurich, Switzerland
Sector:	P3, AgeTech
Investment in Switzerland companies:	aktiia, Memo Therapeutics
Stages:	Early Stage Venture, Seed

Johnson & Johnson Development Corporation



DEVELOPMENT CORPORATION

JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment's performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson's traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.

Web site:	jjdevcorp.com
Number of Investments:	150
Total Investments:	\$230M
Founded in:	1979
Based in:	New Brunswick, NJ, USA
Sector:	P3
Investment in Switzerland companies:	Biocartis
Stages:	Early Stage Venture, Late Stage Venture, Private Equity, Seed

Johnson & Johnson Innovation



INNOVATION

Johnson & Johnson Innovation is a center to science and business experts to collaborate with innovators to incorporate science into healthcare solutions, including medical device and diagnostic technologies, consumer healthcare products, and pharmaceuticals. It is focused on the advancement of new healthcare solutions in the consumer, pharmaceutical, and medical devices and diagnostics sectors.

The company provides financing tools that include early-stage research funding, seed funding, equity investments, licensing, and collaborations. Additionally, it offers its partners access to international markets, pricing and reimbursement, market testing, company creation services, and more.

Web site:	jnjinnovation.com
Number of Investments:	50
Total Investments:	\$34.5M
Founded in:	Undisclosed
Based in:	New Brunswick, NJ, USA
Sector:	P3
Investment in Switzerland companies:	Asceneuron
Stages:	Series A

Life Sciences Partners



LSP is one of Europe's largest and most experienced healthcare investment firms. With a track record going back more than 30 years, company has built up an investment house that is dedicated to only one task: seeking, nurturing and growing healthcare investment opportunities with the potential to have a positive impact on society. They believe such opportunities create the most value for all parties. From their offices in Amsterdam, Munich and Boston, the team aims to back the smartest inventors with the best ideas. While their goal is to develop products and technologies that have a positive impact on society, LSP objective is to help inventors achieve their goals. By definition, success is often accompanied by financial returns. The combination of contributing to society and the prospect of associated financial returns, is why investors entrust LSP to invest their capital alongside LSP's own capital.

Web site:	lspvc.com
Number of Investments:	102
Total Investments:	\$30M
Founded in:	1998
Based in:	Amsterdam, The Netherlands
Sector:	P3
Investment in Switzerland companies:	GTX medical
Stages:	Undisclosed

LifeCare Partners



LifeCare Partners GmbH is a principal investment firm specializing in mezzanine investments. The firm seeks to invest in private and public life science and healthcare industry with special focus on medical technology, diagnostics, bio/pharmaceuticals, generics, food/nutrition, industrial biotechnology, biomaterials, e-health, and bioenergy. It invests in private and public companies. LifeCare Partners GmbH was founded in 2014 and is based in Basel, Switzerland. The company has successfully invested in more than 30 life science companies over the last years, of which a large number have already been listed on the stock exchange or have been acquired by leading players in the life science industry.

Web site:	lifecare.partners
Number of Investments:	6
Total Investments:	\$15.4M
Founded in:	2014
Based in:	Basel, Switzerland
Sector:	P3
Investment in Switzerland companies:	Kuros Biosciences
Stages:	Private Equity

M Ventures



Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck's core business areas. From the headquarters in Amsterdam and offices in the US and Israel they invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck's science and technology base.

Web site:	m-ventures.com
Number of Investments:	49
Total Investments:	\$41M
Founded in:	2009
Based in:	Yavne, Israel
Sector:	P3
Investment in Switzerland companies:	Prexton Therapeutics
Stages:	Early Stage Venture, Late Stage Venture

MassChallenge



In addition to providing expert mentorship, tailored curriculum, and unrivaled access to corporate partners, MassChallenge awards top startups with portions of several million dollars in cash prizes. With accelerators in Boston, Israel, Mexico, Switzerland, Texas, and the UK, MassChallenge strengthens innovation-driven economic development around the world. MassChallenge also runs Bridge to MassChallenge programs in Australia, Columbia, France, Korea, Mexico, Morocco, Poland, Russia, and Spain to drive the creation of high-quality jobs. In 2016, MassChallenge launched PULSE@MassChallenge to accelerate the impact of digital health innovation and improve patient care through technology. To date, 1,211 MassChallenge alumni have raised over \$2 billion in funding, generated approximately \$900 million in revenue, and created over 65,000 total jobs.

Web site:	masschallenge.org
Number of Investments:	1364
Total Investments:	\$100K
Founded in:	2009
Based in:	Boston, MA, USA
Sector:	AgeTech
Investment in Switzerland companies:	Xsensio
Stages:	Grant

MedHoldings

MedHoldings is a Lausanne based Private Equity and Venture Capital investment company, focusing primarily on development and late stage Medtech ventures in Switzerland, Europe and Emerging Markets. It supports innovative technologies and solutions, that target unmet medical needs, provide efficiency and reduce cost of care.

Web site:	-
Number of Investments:	2
Total Investments:	\$6.2M
Founded in:	Undisclosed
Based in:	Lausanne, Switzerland
Sector:	P3
Investment in Switzerland companies:	Abionic
Stages:	Early Stage Venture, Private Equity

Michael J. Fox Foundation



The Michael J. Fox Foundation for Parkinson's Research is a non-profit research and development organization. The foundation focuses on developing medicines, research, and raising funds for the cure of Parkinson's disease. In practice, that means identifying and funding projects most vital to patients; spearheading solutions around seemingly intractable field-wide challenges; coordinating and streamlining the efforts of multiple, often disparate, teams; and doing whatever it takes to drive faster knowledge turns for the benefit of every life touched by PD.

Web site:	michaeljfox.org
Number of Investments:	14
Total Investments:	Undisclosed
Founded in:	2000
Based in:	New York, NY, USA
Sector:	P3
Investment in Switzerland companies:	Asceneuron
Stages:	Grant

MP HealthCare Venture Management

MP Healthcare
Venture Management, Inc.

MP Healthcare Venture Management, Inc. is a jointly owned venture capital arm of Mitsubishi Tanabe Pharma Corp. and Mitsubishi Chemical Holdings Corporation, specializing in seed to late-stage investments. The firm considers investing in lifesciences companies with a focus on biotechnology, therapeutics, diagnostics and vaccines. It prefers to invest in novel drugs and diagnostics in various disease areas, including nephrology, immunology and inflammation, cardiovascular, neuroscience, strokes, and metabolic diseases. The firm typically invests in North America and Europe. It usually invests as part of an investment syndicate with other leading venture capital firms. MP Healthcare Venture Management, Inc. was founded in 2006 and is based in Boston, Massachusetts.

Web site:	mp-healthcare.com
Number of Investments:	28
Total Investments:	\$65.3M
Founded in:	2006
Based in:	Boston, MA, USA
Sector:	P3
Investment in Switzerland companies:	Covagen
Stages:	Early Stage Venture, Seed

Neomed Management



NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date. NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device and diagnostics industries. NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.

Web site:	neomed.net
Number of Investments:	45
Total Investments:	\$20M
Founded in:	1997
Based in:	Oslo, Norway
Sector:	Regenerative Medicine
Investment in Switzerland companies:	Genkyotex
Stages:	Early Stage Venture, Late Stage Venture, Private Equity

Nestle Health Science



As a wholly-owned subsidiary of Nestlé, with global headquarters in Vevey, Switzerland, Nestlé Health Science has a distinct role to play in the Nestlé's transformation into the world's recognised leader in Nutrition, Health and Wellness. At Nestlé Health Science, their specific quest is to become the global leader in science-based personalised nutritional solutions. The company intends to use Nestlé's existing HealthCare Nutrition business to build a leading health science nutrition organisation within two years. It aims to develop a product portfolio and pipeline within five years and establish market leadership, meeting its vision, within a decade from start-up. The company has access to external scientific and technological know-how through Nestlé's innovation network as well as a number of venture capital funds in which the group has interests.

Web site:	nestlehealthscience.com
Number of Investments:	8
Total Investments:	Undisclosed
Founded in:	2011
Based in:	Vevey, Switzerland
Sector:	P3
Investment in Switzerland companies:	Amazentis
Stages:	Undisclosed

Novartis



Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services.

Web site:	novartis.com
Number of Investments:	36
Total Investments:	\$2.8B
Founded in:	1895
Based in:	Basel, Switzerland
Sector:	P3
Investment in Switzerland companies:	Roche
Stages:	Early Stage Venture, Late Stage Venture, Grant

Novartis Venture Fund



Their primary focus is on the development of novel therapeutics and platforms. Company balances the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In the investments they look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. They prefer to have initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Company continues the approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started.

Web site:	nvfund.com
Number of Investments:	193
Total Investments:	\$13.6M
Founded in:	1997
Based in:	Basel, Switzerland
Sector:	P3
Investment in Switzerland companies:	Roche Glycart
Stages:	Early Stage Venture, Late Stage Venture, Post-Ipo, Secondary Market, Seed

Novo Holdings



Established in 1999, Novo Holdings is the holding company of the Novo Group and manages the Foundation's investment assets. In addition to being the major shareholder in the Novo Group companies, Novo Holdings invests the wealth of the Foundation in two key categories: 1) Life Science Investments, which includes investing in life science companies at all stages of development; and 2) Financial Investments, which manages a diversified portfolio of equity and fixed income securities. Working out of Copenhagen, San Francisco and Boston, Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Web site:	novoholdings.dk
Number of Investments:	135
Total Investments:	\$28M
Founded in:	1999
Based in:	Copenhagen, Denmark
Sector:	P3
Investment in Switzerland companies:	NBE-Therapeutics
Stages:	Early Stage Venture, Late Stage Venture, Post-Ipo, Private Equity, Seed

Omega Funds



Omega Funds invests in biotechnology and medical device companies in North America and Western Europe. They have invested in early-stage, disruptive and scalable platform technologies, as well as therapeutics companies with defined products. Omega Funds invests in both private and public companies via primary investments, PIPEs and direct secondaries. Omega has a strategic relationship with NeoMed Management, a Jersey headquartered investment firm, which broadens their capabilities within key European markets and adds expertise in additional therapeutic areas and in medical devices. NeoMed will continue to manage its existing legacy funds, while assisting and advising on new investments for Omega's current fund. Omega's investments have brought to market 33 products.

Web site:	omegafunds.net
Number of Investments:	56
Total Investments:	\$15.4M
Founded in:	2004
Based in:	Boston, MA, USA
Sector:	P3
Investment in Switzerland companies:	Kuros Biosciences
Stages:	Early Stage Venture, Late Stage Venture, Private Equity

Palmarium



Palmarium is a private family office and investor with focus on alternative investments including private equity, venture capital and real estate. Palmarium is a private family office and investor with focus on alternative investments including private equity and real estate. They leverage their networks to identify opportunities and structure proprietary transactions around them, with the unique ability to manage complex businesses and situations. The rare combination of their deep sector knowledge and a singular commitment to their principals and partners is reflected in their performance and diverse portfolio of businesses.

Web site:	palmarium.ch
Number of Investments:	2
Total Investments:	\$4.7M
Founded in:	Undisclosed
Based in:	Zurich, Switzerland
Sector:	P3
Investment in Switzerland companies:	healthbank innovation AG
Stages:	Family Investment Office

PMV Tina Fund



PMV Tina Fund is a closed private equity fund managed by PMV.

PMV-TINA specializes in growth capital investments. It seeks to invest in consortium projects in energy, ecology, and the environment (including smart grids); information and communication technology for socio-economic innovation; new materials, nanotechnology, and the processing industry; medical translational research and research into health and nutrition; information and communication technology and services for the healthcare sector; and logistics, transportation and supply chain management.

Web site:	-
Number of Investments:	5
Total Investments:	\$129M
Founded in:	Undisclosed
Based in:	Brussels, Belgium
Sector:	P3
Investment in Switzerland companies:	Biocartis
Stages:	Late Stage Venture

PPF Group



PPF Group invests into multiple market segments such as banking and financial services, telecommunications, biotechnology, real estate, insurance and agriculture. PPF's reach spans from Europe to Russia, the USA and across Asia. PPF Group owns assets exceeding EUR 24.2 billion (as at 30 June 2016). Their philosophy is to search out business opportunities that others have overlooked or rejected on a risk basis and where they see hidden value. Their aim is to achieve superior investment returns through their values of responsibility, determination and successful execution. The 25-year history of PPF Group is based on the discipline, innovation and professionalism of a team led by the Czech founder and majority shareholder of PPF Group N.V., Petr Kellner.

Web site:	ppfgroup.nl
Number of Investments:	8
Total Investments:	\$28M
Founded in:	1991
Based in:	Amsterdam, The Netherlands
Sector:	P3
Investment in Switzerland companies:	Cellestia Biotech, NBE-Therapeutics
Stages:	Seed, Series A, Series B

Preon Capital Partners



Based in Geneva since 2014, Preon Capital Partners is the family office of one of the most successful business angels in Europe and operates as an independent asset manager and financial advisory company. The company invests mainly in equity with a particular focus in technology startups that try to anticipate future global trends. The liquidity is managed via mutual funds that may invest directly in listed equity, listed derivatives and in external hedge fund managers. Their funds have been designed for and are dedicated to the family office beneficiary owner, but they may be opened to external investors at the directors' discretion.

Web site:	preoncapital.com
Number of Investments:	1
Total Investments:	\$0.15M
Founded in:	2014
Based in:	Geneva, Switzerland
Sector:	P3
Investment in Switzerland companies:	GenomSys
Stages:	Undisclosed

Quest Capital Management



Quest Capital Management, Inc. is a wealth management and comprehensive financial planning company. They focus on creating a Plan for Life™ - a unique financial plan designed to help meet clients' changing needs. Their mission at Quest Capital Management, Inc. is to help the client achieve his financial goals and objectives. Whether he is just getting started with an investment strategy or looking for professional advice on how to maximize his wealth, the company's team of professional financial planners can help him make wise decisions now -- for himself, the family, and the future.

Web site:	questadvisor.com
Number of Investments:	3
Total Investments:	\$13.6M
Founded in:	1987
Based in:	Dallas, TX, USA
Sector:	P3
Investment in Switzerland companies:	Roche Glycart
Stages:	Undisclosed

Redalpine Venture Partners



Redalpine provides venture capital to highly scalable European start-ups. The firm's mission is to help talented entrepreneurs turn an ambitious vision into reality by providing money, experience, coaching and a network. The firm prefers to invest in disruptive business models with a moderate total capital need in the fields of information technology (ICT) and life sciences in seed and early stage. Redalpine started with its first fund (Redalpine Capital I) in 2007 based on the track-record of some excellent trade-sales and IPOs as serial entrepreneurs and professional angel investors. Redalpine successfully launched Redalpine Capital II in 2012 and Redalpine Capital III in 2016. The funds are registered in Luxemburg and backed by dozens of experienced entrepreneurs and investors representing various countries, and a broad range of industries.

Web site:	redalpine.com
Number of Investments:	55
Total Investments:	\$11.3M
Founded in:	2007
Based in:	Zurich, Switzerland
Sector:	P3, AgeTech
Investment in Switzerland companies:	aktiia, Memo Therapeutics
Stages:	Early Stage Venture, Seed, Venture

Seroba Life Sciences



Seroba is a life sciences venture capital firm, focused on investing in breakthrough healthcare technologies that promise to improve lives and make a difference worldwide. Headquartered in Ireland, the firm works with some of the world's best entrepreneurs developing innovative medical devices, diagnostics, and therapeutic drugs. It funds new healthcare opportunities through key value-adding stages, assisting its invested companies from inception through development and clinical evaluation, the generation of intellectual property, regulatory approvals and market launch, and partnering with leading pharmaceutical or medtech companies.

Web site:	seroba-lifesciences.com
Number of Investments:	25
Total Investments:	\$96.2M
Founded in:	2009
Based in:	Dublin, Ireland
Sector:	P3
Investment in Switzerland companies:	Prexton Therapeutics, Covagen
Stages:	Early Stage Venture

Sofinnova Partners



Sofinnova Partners is an independent venture capital firm based in Paris, France. For over 35 years, the firm has backed nearly 500 companies at different stages of development pure creations, spin-offs, as well as turnaround situations and worked alongside Europe key entrepreneurs in the technology, life sciences and cleantech sectors. With 1.1 billion of funds under management, Sofinnova Partners experienced team and hands-on approach in building portfolio companies through to exit have created market leaders, from landmark historical investments including Genentech, Actelion and Vistaprint to more recent successes such as CoreValve, Novoxel and Fovea. With a global mindset, the firm has a sister organization in San Francisco, California.

Web site:	sofinnova.fr
Number of Investments:	200
Total Investments:	\$48.29M
Founded in:	1972
Based in:	Paris, France
Sector:	P3
Investment in Switzerland companies:	Auris Medical
Stages:	Early Stage Venture, Late Stage Venture, Seed

SR One



SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. They have a team of investment professionals, located in the US and UK. As a Team, their experience spans basic science, industry and the market. They take an active role in their portfolio companies and work with management teams and their fellow venture investors to create significant value. Their current portfolio includes approximately 35 private and public companies. Their expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.

Web site:	srone.com
Number of Investments:	136
Total Investments:	\$34.5M
Founded in:	1985
Based in:	Cambridge, MA, USA
Sector:	P3
Investment in Switzerland companies:	Asceneuron
Stages:	Series A, Series C

Sunstone Life Science Ventures



Sunstone Life Science Ventures A/S is a European, early-stage investor based in Copenhagen, investing in therapeutics, medical technology and diagnostics. Initially the investments are made in companies raising Series A/B rounds, but also investments at an earlier stage. Sunstone is passionate about being part of the journey where science is turned into products benefiting patients worldwide, seeking opportunities which improve patient outcome and have the potential of offering solutions that are more efficient for the health care system.

Web site:	sunstone.eu
Number of Investments:	56
Total Investments:	\$41M
Founded in:	2007
Based in:	Copenhagen, Denmark
Sector:	P3
Investment in Switzerland companies:	Prexton Therapeutics
Stages:	Early Stage Venture, Seed

SV Health Investors



SV Health Investors, formerly SV Life Sciences, is a leading healthcare and life sciences venture capital and growth equity firm. Their goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments. With over \$2 billion in capital under management in seven private healthcare funds, a 20-year track record in the US and Europe and offices in Boston, San Francisco and London, SV Health Investors drives game-changing innovation.

Web site:	svhealthinvestors.com
Number of Investments:	208
Total Investments:	\$18M
Founded in:	1993
Based in:	Boston, MA, USA
Sector:	P3
Investment in Switzerland companies:	OncoEthix
Stages:	Debt, Early Stage Venture, Late Stage Venture

Swiss Helvetia Fund



Swiss Helvetia Fund is a non-diversified, closed-end investment company whose objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The Fund also may acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances. The Fund is listed on the New York Stock Exchange under the symbol “SWZ”.

Web site:	schroders.com
Number of Investments:	4
Total Investments:	\$15.4M
Founded in:	1986
Based in:	New York, NY, USA
Sector:	P3
Investment in Switzerland companies:	Kuros Biosciences
Stages:	Early Stage Venture, Late Stage Venture

Swiss Life Private Equity Partners



The Swiss Life Group is one of Europe's leading providers of long-term savings and protection and life insurance. The Swiss Life Group offers individuals and companies comprehensive advice and a broad range of products via agents, brokers and banks in its domestic market, Switzerland, where it is market leader, and selected European markets. Multinational companies are serviced with tailor-made solutions by a network of partners in over fifty countries. The Swiss Life Group, registered in Zurich, was founded in 1857 as the Swiss Life Insurance and Pension Company. Shares of Swiss Life Holding are listed on the SWX Swiss Exchange (SLHN). The company employs around 12 000 persons.

Web site:	swisslife.com
Number of Investments:	5
Total Investments:	\$14M
Founded in:	1857
Based in:	Zürich, Switzerland
Sector:	Regenerative Medicine
Investment in Switzerland companies:	Zeptosens
Stages:	Late Stage Venture

Swisscom Ventures



Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007. Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technical expertise and strategic insights of an incumbent telecom operator.

Web site:	ventures.swisscom.com
Number of Investments:	81
Total Investments:	\$2.8M
Founded in:	2007
Based in:	Zurich, Switzerland
Sector:	P3
Investment in Switzerland companies:	Scailyte
Stages:	Convertible Note, Early Stage Venture, Late Stage Venture, Seed

Tilocor Life Science

Tilocor Life Science provides financial support for the Tilocor Group's newly created companies, acquisitions and investments. Co-founded by Professor Stefan Catsicas, former Vice-President of the Swiss Federal Institute of Technology (Lausanne), Tilocor promotes an entrepreneurial approach adapted to the long-term needs of the life science sector. Its main goal is to launch product-oriented biotechnology companies and to invest in existing promising early stage companies worldwide.

Web site:	-
Number of Investments:	3
Total Investments:	\$41M
Founded in:	2005
Based in:	Luxembourg, Luxembourg
Sector:	P3
Investment in Switzerland companies:	Xigen
Stages:	Early Stage Venture

TransLink Capital



TransLink Capital is a venture capital firm specializing in investments in seed, start-ups, and early and expansion stage companies. The firm prefers to invest in the information technology, mobile, social and cloud applications, infrastructure and services, fintech, communications, and digital media sectors. It also seeks to invest in consumer facing technology with a focus on artificial intelligence, virtual reality, e-sports, live streaming videos, and robotics.

Web site:	translinkcapital.com
Number of Investments:	111
Total Investments:	\$4M
Founded in:	2007
Based in:	Palo Alto, CA, USA
Sector:	AgeTech
Investment in Switzerland companies:	aktiia
Stages:	Early Stage Venture, Late Stage Venture, Seed

The Bill & Melinda Gates Foundation

BILL & MELINDA
GATES *foundation*

The Bill & Melinda Gates Foundation is a grant-making foundation that supports initiatives in education, world health and population, and community giving in the Pacific Northwest. In its local region, the foundation promotes strategies and programs that help low income families. The Bill & Melinda Gates Foundation has offices in New Delhi, India; Beijing, China; and London, United Kingdom. Its trustees are Bill and Melinda Gates, and Warren Buffett. The Bill & Melinda Gates Foundation`s Program Teams are Global Health, Global Development, Global Policy, Advocacy & Communications, Global Growth and Opportunity, and US Programs. They research and make grant & investment proposals that are aligned with a program strategy. They are responsible for ongoing management of grants and investments.

Web site:	gatesfoundation.org
Number of Investments:	108
Total Investments:	\$100M
Founded in:	2000
Based in:	Seattle, WA, USA
Sector:	P3
Investment in Switzerland companies:	Novartis
Stages:	Early Stage Venture, Grant, Late Stage Venture

TVM Capital



TVM Capital GMBH is private equity and venture capital firm specializing in seed, startup, early stage, mid, late stage, emerging growth, growth capital and buyout investments. It seeks to invest in companies that have spun-out from institutes, universities, and the Research and Development departments of pharmaceutical companies. The firm may also invest in family owned businesses and in all stages of the product life cycle from its earliest stages like material and design innovation through late stage opportunities brought about by business model and execution innovation.

Web site:	tvm-capital.com
Number of Investments:	96
Total Investments:	\$45.9M
Founded in:	1983
Based in:	Munich, Germany
Sector:	Regenerative Medicine
Investment in Switzerland companies:	Vivendy Therapeutics
Stages:	Early Stage Venture, Late Stage Venture, Private Equity

Ventech



Created in 1998, Ventech is a venture capital firm specializing in early-stage investments in startup companies. It has a broad investment scope with the capacity to invest in B2B and in B2C, in software and in hardware, with an industry agnostic approach.

The firm's primary geographical focuses are, for the European fund, France, DACH region and the Nordics, with offices in Paris, Munich and Helsinki. Ventech China invests in Asia with an office in Shanghai.

Web site:	ventechvc.com
Number of Investments:	157
Total Investments:	\$99.4M
Founded in:	1998
Based in:	Paris, France
Sector:	P3
Investment in Switzerland companies:	Covagen
Stages:	Early Stage Venture, Late Stage Venture, Seed

Venture Incubator



Venture Incubator, LLC, a 501c(3) non-profit corporation was formed in April, 2011 as a result of a three year study funded by the Downtown Jackson Partners to evaluate the feasibility of opening a business incubator in the business district of Downtown Jackson, MS. With support from Jeffrey Rupp, Director of the Technology Resource Institute at Mississippi State University, a joint venture between his organization and Venture Incubator was formed. The goal is to leverage existing economic development resources to deliver quality entrepreneur training and assistance directly to the entrepreneurs and emerging businesses around the State of Mississippi. Venture Incubator offers entrepreneurs and business owners an opportunity to limit expenses by delivering access to seasoned professionals and business coaches directly to their local area.

Web site:	-
Number of Investments:	3
Total Investments:	\$7.9M
Founded in:	2011
Based in:	Jackson, MS, USA
Sector:	P3, Regenerative Medicine
Investment in Switzerland companies:	Covalys Biosciences, Kuros Biosciences
Stages:	Undisclosed

Venture Kick



The philanthropic initiative Venture Kick provides as much as 150,000 Swiss francs seed stage financing to startups. In addition, it offers a well-structured entrepreneurial path towards building a winning business. Startups pitch to expert juries at each stage to obtain funding, gaining direct feedback and access to an international network of successful entrepreneurs and investors. Since its launch in 2007, Venture Kick has supported 600 Swiss startup projects with 24.86 million francs. The program of financial support, training and network, has led to the creation of more than 445 companies and more than 5,000 jobs.

Web site:	venturekick.ch
Number of Investments:	389
Total Investments:	\$640M
Founded in:	2007
Based in:	Schlieren, Switzerland
Sector:	P3
Investment in Switzerland companies:	Amal Therapeutics, ABCDx
Stages:	Seed

Versant Ventures



Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With \$2.3 billion under management and offices in Canada, the U.S. and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm's founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.

Web site:	versantventures.com
Number of Investments:	289
Total Investments:	\$51M
Founded in:	1999
Based in:	Menlo Park, CA, USA
Sector:	P3
Investment in Switzerland companies:	PIQUR Therapeutics
Stages:	Debt, Early Stage Venture, Late Stage Venture, Private Equity

Vesalius Biocapital Partners



Vesalius Biocapital Partners manages a mid-size venture capital fund that invests in young, early and mid-stage European life science companies creating innovative drugs, diagnostics and cutting-edge biomedical technologies. With more than €150 million under management in two funds, Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financing rounds. Vesalius Biocapital Partners finance both early stage companies and corporate spin-offs with more mature assets.

Web site:	vesaliusbiocapital.com
Number of Investments:	30
Total Investments:	\$81.8M
Founded in:	2007
Based in:	Strassen, Luxembourg
Sector:	Regenerative Medicine
Investment in Switzerland companies:	Genkyotex
Stages:	Early Stage Venture, Late Stage Venture

VI Partners



Healthcare & Technology Venture Capital since 2001. They build bridges between entrepreneurs' dreams and successful companies. They enable savvy investors to partner with the best start-up companies. VI Partners is a Swiss venture capital firm providing university spin-off's as well as other promising start-up companies with capital, coaching and networks. VI Partners is the advisor to Venture Incubator (VI). VI was established by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ) in 2001. VI is an evergreen fund with a paid in capital of CHF 101m. The investors are 10 Swiss blue-chip companies from industry and finance.

Web site:	vipartners.ch
Number of Investments:	63
Total Investments:	\$224.6M
Founded in:	2001
Based in:	Altendorf, Switzerland
Sector:	P3, Regenerative Medicine
Investment in Switzerland companies:	Amal Therapeutics, CeQur, Kuros Biosciences, Genkyotex, Covalys Biosciences
Stages:	Early Stage Venture, Late Stage Venture, Seed

Wellington Partners



Wellington Partners is one of the most successful pan-European venture capital firms. With funds totalling over €800 million, company has invested throughout Europe in companies that have the potential to become real market leaders for more than 15 years. Providing funding is only one part of the business. After funding, the entrepreneurs they back have access to the advice and guidance of complete team and company's entire global network. Investment professionals operate out of four offices, located in London, Munich, Zurich and Palo Alto. The pan-European and transatlantic makeup of the organisation enables them to support portfolio in expanding globally.

Web site:	wellington-partners.com
Number of Investments:	186
Total Investments:	\$30M
Founded in:	1998
Based in:	Munich, Germany
Sector:	P3
Investment in Switzerland companies:	GTX Medical (G-Therapeutics)
Stages:	Debt, Early Stage Venture, Late Stage Venture, Private Equity, Seed

Woodford Investment Management

The logo for Woodford, featuring the word "woodford" in a lowercase, sans-serif font. The letter "w" is underlined. The logo is enclosed in a dashed blue rectangular border.

Woodford Investment Management is a privately owned investment firm manages equity mutual funds. As investors, they are active, engaged, long-term, disciplined, diligent and focused. That's a lot of things to say about themselves but each word is important in helping you to understand how they manage money – they will explain in more detail as they move along. Their investment approach and process are focused on value discovery, not price discovery. They believe that financial markets are inherently inefficient and that, through disciplined and diligent analysis, they can identify investment opportunities where market prices do not reflect long-term fundamental value. By exploiting this pervasive market characteristic, they believe they can create real long-term value for their investors.

Web site:	woodfordfunds.com
Number of Investments:	61
Total Investments:	\$100M
Founded in:	2014
Based in:	Oxford, UK
Sector:	P3
Investment in Switzerland companies:	CeQur
Stages:	Early Stage Venture, Private Equity


Ysios Capital

YSIOS CAPITAL

Founded in 2008, Ysios Capital has over €200 million in assets under management through its two funds: Ysios BioFund I (€65M) and Ysios BioFund II Innvierte (€126M). They aim to create value by providing talented entrepreneurs with the resources and tools to achieve success in transforming intellectual capital and scientific knowledge into successful companies. Their team includes experienced professionals with extensive complementary expertise in investing and building healthcare and biotechnology companies.

Web site:	ysioscapital.com
Number of Investments:	40
Total Investments:	\$41M
Founded in:	2008
Based in:	Barcelona, Spain
Sector:	P3
Investment in Switzerland companies:	Prexton Therapeutics
Stages:	Early Stage Venture, Late Stage Venture, Venture

Zürcher Kantonalbank ZKB



Zürcher
Kantonalbank

Zurich Cantonal Bank is the largest cantonal bank and fourth largest bank in Switzerland, as well as the leading financial services provider in the Greater Zurich area, with total assets of over CHF 150 billion. Ultimate supervision of ZKB is the responsibility of the Cantonal Council of Zurich, whose duties are laid down in Zurich's Cantonal Bank Act. Under the law, the canton of Zurich bears responsibility for all ZKB's liabilities should the bank's resources prove inadequate. This cantonal guarantee acts as a stabilising force for the financial market as a whole, particularly in times of economic uncertainty. On October 2009, Global Finance magazine rated ZKB at one of the five safest banks in the world, on the basis of it being one of only five financial institutions that enjoyed a triple Standard & Poor's, Fitch and Moody's AAA/Aaa rating globally.

Web site:	zkb.ch
Number of Investments:	72
Total Investments:	Undisclosed
Founded in:	1870
Based in:	Zurich, Switzerland
Sector:	P3
Investment in Switzerland companies:	Scailyte
Stages:	Undisclosed